Issue 3 2007
Featuring
RNAi: an attractive choice for future therapeutics
John J. Rossi, Division of Molecular Biology, Beckman Research Institute of the City of Hope discusses RNAi as an attractive choice for future therapeutics
Biomarker discovery and validation in clinical proteomics
Professor Stephen R. Pennington, Proteome Reserch Centre, Conway Institute of Biomolecular and Biomedical Sciences, University College Dublin
The handling and analysis of large scale high content screening data
Karol Kozak and Benjamin Eshun, Max Planck Institute of MolecularCell Biology and Genetics look at the handling and analysis of large scale high content screening data
Launching an HTS campaign to discover new antivirals
Colleen B. Jonsson, Ph.D., Program Leader, emerging Infectious Disease Research and E. Lucile White, Manager, High-Throughput Screening Center and Enzymology Laboratory, Southern Research Institute give us an insight into discovering new antivirals
Calorimetry for amorphous content quantification
Simon Gaisford PhD., ans Rita Ramos PhD., School of Pharmacy, University of London
Ion Channel electrophysiology in pharmaceutical research
Daniel Konrad, Simon Hebeisen, and Urs Thomet, bSys GmbH highlight the role of ion channel electrophysiology in pharmaceutical research
Automated classification of crystallisation images
Julie Wilson, York Structural Biology Laboratory, Department of Chemistry, University of Heslington, UK
Spray-freeze-drying in the manufacture of pharmaceuticals
Heiko A. Schiffter, Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, UK examines spray-freeze-drying of pharmaceuticals
PAT and design science
Carl-Fredrik Mandenius, Micael Derelov, Jonas Detterfelt, Mats Bjorkman, Division of biotechnology/IFM and Division of Production Systems, IKP, Linkoping University, Sweden discuss taking advantage of experiences from another scienctific area - conceptual design science
EuPAT: an initiative to promote progress in the science underpinning PAT
Staffan Folestad, Senior Principal Scientist, AstraZeneca, Sweden; Peter York, Bradford University, UK and Rasmus Bro, Copenhagen University, Denmark
The significance and detection of VBNC microorganisms
Dr Paul Newby, Team Leader, Pharmaceutical Microbiology, GlaxoSmithKline
If you wish to view the magazine in PDF format (size: 1.59 MB), please click HERE